Monocyte Chemoattractant Protein-1 (MCP-1) as a Potential Therapeutic Target and a Noninvasive Biomarker of Liver Fibrosis Associated With Transient Myeloproliferative Disorder in Down Syndrome

J Pediatr Hematol Oncol. 2017 Jul;39(5):e285-e289. doi: 10.1097/MPH.0000000000000809.

Abstract

Liver fibrosis is one of the common complications of transient myeloproliferative disorder (TMD) in Down syndrome (DS), but the exact molecular pathogenesis is largely unknown. We herein report a neonate of DS with liver fibrosis associated with TMD, in which we performed the serial profibrogenic cytokines analyses. We found the active monocyte chemoattractant protein-1 expression in the affected liver tissue and also found that both serum and urinary monocyte chemoattractant protein-1 concentrations are noninvasive biomarkers of liver fibrosis. We also showed a prospective of the future anticytokine therapy with herbal medicine for the liver fibrosis associated with TMD in DS.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Chemokine CCL2 / analysis*
  • Cytokines / analysis
  • Diagnosis, Differential
  • Down Syndrome / complications*
  • Humans
  • Infant, Newborn
  • Leukemoid Reaction / complications*
  • Liver / chemistry
  • Liver / pathology
  • Liver Cirrhosis / diagnosis*
  • Liver Cirrhosis / etiology

Substances

  • Biomarkers
  • Chemokine CCL2
  • Cytokines

Supplementary concepts

  • Myeloproliferative Syndrome, Transient